OnKure Therapeutics reported net income of -$15.36M for the quarter ended Jun 2026. This income statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & Cost | ||||||||||||||||||||||||||
| Interest income | ||||||||||||||||||||||||||
| Interest Income - Total | 0.29M | 0.23M | 0.17M | 1.31M | 1.07M | 0.93M | 0.80M | 0.63M | 0.46M | 1.55M | ||||||||||||||||
| Interest expenses | ||||||||||||||||||||||||||
| Interest ExpensesInterest Expense | 0.03M | 0.22M | 0.06M | 0.00M | 0.01M | |||||||||||||||||||||
| Interest Income - Net | 0.20M | -0.04M | 1.26M | 1.07M | 0.93M | 0.80M | 0.62M | 0.46M | 1.55M | |||||||||||||||||
| Non-interest income | ||||||||||||||||||||||||||
| Investment Gain (Loss) | -0.05M | |||||||||||||||||||||||||
| Non-Interest Income | -0.05M | |||||||||||||||||||||||||
| Operating Items | ||||||||||||||||||||||||||
| Research & DevelopmentR&D | 9.32M | 7.10M | 9.28M | 8.13M | 9.94M | 10.36M | 10.99M | 14.40M | 13.62M | -6.89M | 8.57M | 10.75M | 10.12M | 14.36M | 13.01M | 12.61M | 11.91M | 10.72M | 11.71M | 12.61M | ||||||
| Selling, General & AdministrativeSG&A | 3.43M | 3.52M | 3.74M | 4.30M | 3.90M | 4.21M | 5.13M | 6.64M | 7.27M | -14.22M | 1.26M | 3.59M | 1.40M | 4.34M | 3.99M | 3.71M | 3.59M | 3.40M | 3.91M | 4.29M | ||||||
| Operating ExpensesOpex | 12.75M | 10.62M | 13.02M | 12.43M | 13.84M | 14.56M | 16.12M | 21.04M | 20.89M | -21.11M | 9.83M | 14.34M | 11.51M | 18.70M | 17.00M | 16.32M | 15.50M | 14.12M | 15.62M | 16.90M | ||||||
| Operating IncomeOp. Inc | -12.75M | -10.62M | -13.02M | -12.43M | -13.84M | -14.56M | -16.12M | -21.04M | -20.89M | 21.11M | -9.83M | -14.34M | -11.51M | -18.70M | -17.00M | -16.32M | -15.50M | -14.12M | -15.62M | -16.90M | ||||||
| EBIT | -12.75M | -10.62M | -13.02M | -12.43M | -13.84M | -14.56M | -16.12M | -21.04M | -20.89M | 21.11M | -9.83M | -14.34M | -11.51M | -18.70M | -17.00M | -16.32M | -15.50M | -14.12M | -15.62M | -16.90M | ||||||
| Non-operating items | ||||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.03M | 0.22M | 0.06M | 0.00M | 0.01M | |||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.29M | 1.07M | ||||||||||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.02M | 0.02M | -0.02M | 0.12M | 0.83M | 0.96M | 1.02M | 1.51M | 1.69M | 1.45M | 1.14M | 1.00M | 0.97M | |||||||||||||
| Net income details | ||||||||||||||||||||||||||
| EBT | -12.75M | -10.62M | -13.02M | -12.43M | -13.84M | -14.56M | -16.12M | -21.04M | -20.89M | 21.11M | -9.54M | -14.37M | -11.73M | -18.76M | -15.93M | -16.32M | -15.50M | -14.13M | -15.62M | -16.90M | ||||||
| Profit After TaxPAT | -12.73M | -10.61M | -13.04M | -12.31M | -13.20M | -13.62M | -15.11M | -19.53M | -19.20M | 18.52M | -9.54M | -14.14M | -11.56M | -17.44M | -15.93M | -15.39M | -14.70M | -13.50M | -15.16M | -15.36M | ||||||
| Income from Continuing OperationsIncome (Continuing) | -12.75M | -10.62M | -13.02M | -12.43M | -13.84M | -14.56M | -16.12M | -21.04M | -20.89M | 21.11M | -9.54M | -14.37M | -11.73M | -18.76M | -15.93M | -16.32M | -15.50M | -14.13M | -15.62M | -16.90M | ||||||
| Consolidated Net IncomeConsol Net Inc. | -12.75M | -10.62M | -13.02M | -12.43M | -13.84M | -14.56M | -16.12M | -21.04M | -20.89M | 21.11M | -9.54M | -14.37M | -11.73M | -18.76M | -15.93M | -16.32M | -15.50M | -14.13M | -15.62M | -16.90M | ||||||
| Income towards Parent CompanyParent Net Inc | -12.75M | -10.62M | -13.02M | -12.43M | -13.84M | -14.56M | -16.12M | -21.04M | -20.89M | 21.11M | -9.54M | -14.37M | -11.73M | -18.76M | -15.93M | -16.32M | -15.50M | -14.13M | -15.62M | -16.90M | ||||||
| Net Income towards Common StockholdersNet Income | -12.75M | -10.62M | -13.02M | -12.43M | -13.84M | -14.56M | -16.12M | -21.04M | -20.89M | 21.11M | -9.54M | -14.37M | -11.73M | -18.76M | -15.93M | -16.32M | -15.50M | -14.13M | -15.62M | -16.90M | ||||||
| Additional items | ||||||||||||||||||||||||||
| EPS (Basic) | -5.23 | -5.86 | -5.32 | -5.08 | -5.65 | -5.94 | -6.44 | -6.96 | -6.18 | 6.88 | -2.85 | -4.30 | -3.51 | -5.44 | -1.19 | -1.21 | -1.15 | -1.05 | -1.14 | -0.34 | ||||||
| EPS (Diluted) | -5.23 | -5.86 | -5.32 | -5.08 | -5.65 | -5.94 | -6.44 | -6.96 | -6.18 | 6.88 | -2.85 | -4.30 | -3.51 | -5.44 | -1.19 | -1.21 | -1.15 | -1.05 | -1.14 | -0.34 | ||||||
| Shares Outstanding | 2.44M | 1.81M | 2.45M | 2.45M | 2.45M | 2.45M | 2.50M | 3.02M | 3.38M | 3.07M | 3.34M | 3.34M | 3.34M | 3.45M | 13.42M | 13.51M | 13.53M | 13.52M | 13.67M | 49.87M | ||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 2.44M | 1.81M | 2.45M | 2.45M | 2.45M | 2.45M | 2.50M | 3.02M | 3.38M | 3.07M | 3.34M | 3.34M | 3.34M | 3.45M | 13.42M | 13.51M | 13.53M | 13.52M | 13.67M | 49.87M | ||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 2.44M | 1.81M | 2.45M | 2.45M | 2.45M | 2.47M | 13.34M | 13.34M | 13.34M | 13.34M | 13.34M | 13.34M | 13.34M | 13.35M | 12.76M | 12.84M | 12.86M | 13.67M | 13.67M | 40.50M | ||||||
| EBITDA | -12.75M | -10.62M | -13.02M | -12.43M | -13.84M | -14.56M | -16.12M | -21.04M | -20.89M | 21.11M | -9.83M | -14.34M | -11.51M | -18.70M | -17.00M | -16.32M | -15.50M | -14.12M | -15.62M | -16.90M |